On 19 October 2026, the FDA issued a final guide to the notification of new dietary compositions (NDIs), making recommendations on the identity of the ingredients in the notification information, on the historical or other safety evidence used in the past, and on the basis of safety findings. The guide finalized some sections of the draft revised 2016 FDA, not all of which were finalized. Enterprises planning to sell NDI food supplements in the United States may inspect the notification material accordingly; The specific notification obligation should still be judged on the basis of existing legal regulations.
What is this file, at what stage?
File Name New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry, docket FDA-2025-D-6501. This final FDA guidance for industry finalizes the 2016 revised draft sections VI.A, VI.B and VI.C on identity information, history of use or other safety evidence, and the basis for concluding safety. FDA says it is still reviewing the other sections.
The guide represents the current view of FDA and does not create legally binding responsibilities on its own. Pre-market notification obligation, where applicable, from FD&C Act section 413(a)(2) and 21 CFR 190.6.
Which enterprises and products need attention?
| Products | Business roles | Activities requiring attention |
|---|---|---|
| Food supplement with new dietary composition | Manufacturer or distributor of components | To determine whether to trigger NDIN and to prepare identity and security information |
| Food supplement with NDI | Manufacturers or distributors of products | Where applicable, submit a notice before listing, indicating the basis for the security findings |
| Products that do not contain NDI or may not trigger notification | Manufacturers or distributors | Case-by-case judgement based on constituent identity, historical use and statutory definition |
Whether it belongs to NDI, whether it triggers a notification depends on composition and product-specific facts and cannot be determined solely on the basis of a trade name or supplier statement.
Where is the change from what was previously requested?
| Matters | Prior status | This document |
|---|---|---|
| Identity information | Relevant recommendations in the 2016 revised draft | Part VI.A of the recommendation now provides final guidance |
| Use of historical and security evidence | Relevant recommendations in the draft | Part VI.B is now the final guide |
| Basis for security conclusions | Relevant recommendations in the draft | Part VI.C is now the final guide |
| Other chapters of the draft | Not all finalized | FDA says it's still under review. |
This is only the final determination of the above-mentioned parts, not the entire 2016 draft.
Key dates and transitional arrangements
- October 19, 2026: FDA issued its final guide.
- Where applicable, NDIN must be submitted at least 75 days before the NDI product enters interstate commercial circulation; This is the current statutory period and not the new period for the Guide.
- The guide does not set a separate effective date or transition period. FDA indicates that the public may submit comments relevant to the Guide at any time.
The date of the station’s publication is recorded separately from the date of the statute.
How can Chinese companies prepare?
The following is a proposal for the preparation of ALL REG, not a new FDA mandatory requirement:
- Combination of the name, source, specification, mode of manufacture and level of use in the product.
- NDI identity and notification obligations are judged on the basis of legislation and product facts, and the basis for the determination is retained.
- Collating identification information against the guide, using historical or other security evidence, as well as justification of safety findings.
- Check whether the evidence corresponds to the composition, dose, mode of use and labelling conditions of the product to be sold.
- Provide for a minimum of 75 days of required submission window time, where applicable, and consider the possible impact of additional material on the timing.
- Maintenance of research, supply chain documents, version records and audit records.
Exceptions, pending confirmations and common misreading
- The final guide is the recommendatory document, and the statutory obligation should be returned to the FD&C Act and applicable legislation are checked.
- The FDA finalized only some chapters, while other draft elements remain to be followed up.
- Submission of NDIN does not amount to FDA approval or certification of products.
- NDI identification and notification applicability are determined by reference to composition, history of use and product facts.
Official information and reconciliation records
- FDA,New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for IndustryOctober 2026, case file FDA-2025-D-6501:Final guidance。
- FDA,FDA Issues Guidance on Identity and Safety Information for New Dietary Ingredient NotificationsOctober 19, 2026:Announcement。
- Statutory basis: FD&C Act § 413(a)(2);21 CFR 190.6。
Official page reconciliation date: 2 November 2026.
Next
Enterprises can first collate the composition identity, security information and proposed time for listing, and then check whether the product triggers the NDIN and information gaps. Viewable Food FDA Compliance Services Overview orContact All REGScope of communication.
View Food FDA Compliance ServiceView pricing and order online ↗